Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Dose-escalation Phase I Tolerability, Safety, Pharmacokinetics and Efficacy of Purinostat Mesylate (PM) for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant Hematologic Tumors Clinical Trials for Pharmacodynamic Evaluation

NCT05526313 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT05526313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05526313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Dose-escalation Phase I Tolerability, Safety, Pharmacokinetics and Efficacy of Purinostat Mesylate (PM) for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant Hematologic Tumors Clinical Trials for Pharmacodynamic Evaluation
Lead sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
August 10, 2020
Completion date
March 29, 2024
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma，dlbcl